Business
OncBioMune to Present Abstract on Clinical Trial of Novel Prostate Cancer Vaccine at American Association of Cancer Research Special Conference
OncBioMune to Present Abstract on Clinical Trial of Novel Prostate Cancer Vaccine at American Association of Cancer Research Special Conference.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nOncBioMune to Present Abstract on Clinical Trial of Novel Prostate Cancer Vaccine at American Association of Cancer Research Special Conference\n\nOncBioMune to Present Abstract on Clinical Trial of Novel Prostate Cancer Vaccine at American Association of Cancer Research Special Conference\n\nBATON ROUGE, LA--(Marketwired - August 29, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer vaccine technology and commercialization of a portfolio of products internationally, is pleased to announce that Dr. Jonathan Head, Chief Executive Officer and Chairman at OncBioMune, will be presenting an abstract at the upcoming American Association of Cancer Research (AACR) Special Conference taking place October 1-4, 2017 at the Boston Marriott Copley Place in Boston, MA.At the AACR Conference on Tumor Immunology and Immunotherapy, Dr. Head will present an abstract titled, \"Preliminary results of a Phase 1a clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer vaccine in PSA defined biochemical recurrent prostate cancer patients.\" On August 24, 2017, the Company announced that the final patient in the Phase 1a portion of the trial had completed treatment of ProscaVax, OncBioMune's novel therapeutic prostate cancer vaccine. Per protocol, the patient will be evaluated 30 days post-treatment for the primary endpoint of determining safety and tolerability of the vaccine, with a secondary endpoint of signs of efficacy. To date, ProscaVax has demonstrated a strong safety profile, with no dose limited adverse events related to the vaccine reported in the study.\"ProscaVax is a very promising treatment addressing an area of unmet medical need in prostate cancer,\" commented Dr. Head. \"Given all the industry attention immunotherapies are receiving, I suspect that there will continue to be significant interest in the latest data from our study. I look forward to the opportunity to network with peers and discuss ProscaVax at AACR's special conference.\"Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/. About OncBioMune Pharmaceuticals, Inc.OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical company engaged in the development of novel cancer imm...